Time for Action on Viral Hepatitis.
- Author:
Seng Gee LIM
1
Author Information
1. Division of Gastroenterology and Hepatology, National University Health System, Singapore.
- Publication Type:Journal Article
- MeSH:
Antiviral Agents;
therapeutic use;
Disease Outbreaks;
prevention & control;
Health Services Accessibility;
Hepatitis B Vaccines;
therapeutic use;
Hepatitis B, Chronic;
drug therapy;
epidemiology;
prevention & control;
Hepatitis C, Chronic;
drug therapy;
epidemiology;
Humans;
Patient Selection;
Risk Assessment;
Singapore;
epidemiology
- From:Annals of the Academy of Medicine, Singapore
2016;45(1):27-30
- CountrySingapore
- Language:English
-
Abstract:
The recent outbreak of hepatitis C virus (HCV) at Singapore General Hospital (SGH) has highlighted the dangers of viral hepatitis. In this case, infection control and environmental contamination were the culprits, particularly, a drop of blood containing 5 million IU HCV. From a broader perspective, there has been a revolution in HCV therapy with the recent rapid evolution of short-term (12 weeks) safe, all oral directly- acting antiviral (DAA) therapy leading to cure rates of 90% to 100%, even in previously difficult to treat patients with liver cirrhosis, previous treatment failure and those on immunosuppression. Consequently, treating HCV in risk groups such as renal dialysis and haemophiliacs can eliminate a pool of infected patients to prevent future outbreaks. A seroprevalence study is needed to identify a possible "birth cohort" effect that could aid screening. For HBV, vaccination has reduced prevalence to 3.8%, but these patients are prone to complications such as HBV flares. Since 2014, 13 patients developed liver failure and were listed for liver transplantation at National University Hospital (NUH) but 6 died beforehand. This avoidable catastrophe is due to undiagnosed HBV infection or patients who did not return for follow-up. Good antiviral therapy is available, but the issues are similar to HCV, identification of patients and linkage to care. A cure seems likely in the future as pharmaceutical companies are developing new agents. Singapore has joined in this initiative with a recent award of a national research translational grant to better understand the pathophysiology and the processes needed for a cure of HBV.
